Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma

Anneleen Daemen, Jonathan E. Cooper, Szymon Myrta, Matthew J. Wongchenko, Eva Lin, Jason E. Long, Oded Foreman, Zora Modrusan, Jarrod R. Tremayne, Cecile C. de la Cruz, Mark Merchant, Scott E. Martin, Yibing Yan, Melissa R. Junttila

Clin Cancer Res (2021) 27 (4): 1162–1173.

https://doi.org/10.1158/1078-0432.CCR-20-1835

Published: 15 February 2021

View article titled, Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma

Includes: Supplementary data

Journal Articles

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma

Antoni Ribas, Adil Daud, Anna C. Pavlick, Rene Gonzalez, Karl D. Lewis, Omid Hamid, Thomas F. Gajewski, Igor Puzanov, Matthew Wongchenko, Isabelle Rooney, Jessie J. Hsu, Yibing Yan, Erica Park, Grant A. McArthur

Clin Cancer Res (2020) 26 (1): 46–53.

https://doi.org/10.1158/1078-0432.CCR-18-4180

Published: 03 January 2020

View article titled, Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma

Includes: Supplementary data

Journal Articles

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAF^V600-mutated Metastatic Melanoma

Yibing Yan, Matthew J. Wongchenko, Caroline Robert, James Larkin, Paolo A. Ascierto, Brigitte Dréno, Michele Maio, Claus Garbe, Paul B. Chapman, Jeffrey A. Sosman, Zhen Shi, Hartmut Koeppen, Jessie J. Hsu, Ilsung Chang, Ivor Caro, Isabelle Rooney, Grant A. McArthur, Antoni Ribas

Clin Cancer Res (2019) 25 (11): 3239–3246.

https://doi.org/10.1158/1078-0432.CCR-18-0720

Published: 01 June 2019

View article titled, Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma

Includes: Supplementary data

Journal Articles

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma

Inês Pires da Silva, Kevin Y.X. Wang, James S. Wilmott, Jeff Holst, Matteo S. Carlino, John J. Park, Camelia Quek, Matthew Wongchenko, Yibing Yan, Graham Mann, Douglas B. Johnson, Jennifer L. McQuade, Rajat Rai, Richard F. Kefford, Helen Rizos, Richard A. Scolyer, Jean Y.H. Yang, Georgina V. Long, Alexander M. Menzies

Clin Cancer Res (2019) 25 (4): 1272–1279.

https://doi.org/10.1158/1078-0432.CCR-18-1680

Published: 15 February 2019

View article titled, Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma

Includes: Supplementary data

Journal Articles

Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib

Matthew J. Wongchenko, Grant A. McArthur, Brigitte Dréno, James Larkin, Paolo A. Ascierto, Jeffrey Sosman, Luc Andries, Mark Kockx, Stephen D. Hurst, Ivor Caro, Isabelle Rooney, Priti S. Hegde, Luciana Molinero, Huibin Yue, Ilsung Chang, Lukas Amler, Yibing Yan, Antoni Ribas

Clin Cancer Res (2017) 23 (17): 5238–5245.

https://doi.org/10.1158/1078-0432.CCR-17-0172

Published: 31 August 2017

View article titled, Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib

Includes: Supplementary data

Journal Articles

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Clin Cancer Res (2015) 21 (1): 77–86.

https://doi.org/10.1158/1078-0432.CCR-14-0947

Published: 05 January 2015

View article titled, First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Includes: Supplementary data

Journal Articles

Pathway activation signatures of breast cancer predict molecular subtype and drug sensitivity

Zachary Boyd, Jenny Wu, Yibing Yan, Lukas Amler, Mark Lackner

Clin Cancer Res (2008) 14 (19_Supplement): A31.

Published: 15 August 2014

View article titled, Pathway activation signatures of breast cancer predict molecular subtype and drug sensitivity

Journal Articles

High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing

Richard Bourgon, Shan Lu, Yibing Yan, Mark R. Lackner, Weiru Wang, Victor Weigman, David Wang, Yinghui Guan, Lisa Ryner, Hartmut Koeppen, Rajesh Patel, Garret M. Hampton, Lukas C. Amler, Yulei Wang

Clin Cancer Res (2014) 20 (8): 2080–2091.

https://doi.org/10.1158/1078-0432.CCR-13-3114

Published: 15 April 2014

View article titled, High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing

Includes: Supplementary data

Journal Articles

Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068

Clin Cancer Res (2013) 19 (24): 6976–6986.

https://doi.org/10.1158/1078-0432.CCR-13-0978

Published: 16 December 2013

View article titled, Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068

Includes: Supplementary data

Journal Articles

Abstract PR6: Widespread potential for growth factor-driven resistance to anti-cancer kinase inhibitors

Timothy R. Wilson, Jane Fridlyand, Antoni Ribas, Jiang Li, Hartmut Koeppen, Mark Merchant, Richard Neve, Jeff Settleman, Yibing Yan, Elicia Penuel, Luciana Burton, Emily Chan, Jing Peng, Eva Lin, Yulei Wang, Jeff Sosman

Clin Cancer Res (2012) 18 (10_Supplement): PR6.

https://doi.org/10.1158/1078-0432.MECHRES-PR6

Published: 04 March 2013

View article titled, Abstract PR6: Widespread potential for growth factor-driven resistance to anti-cancer kinase inhibitors

Journal Articles

Abstract A29: Different PIK3CA activation mutations can lead to distinct signaling mechanisms and EGFR inhibitor sensitivities in colorectal cancer cells

Matthew J. Wong, Marie-Claire Wagle, Garret Hampton, Yibing Yan

Clin Cancer Res (2012) 18 (10_Supplement): A29.

https://doi.org/10.1158/1078-0432.MECHRES-A29

Published: 04 March 2013

View article titled, Abstract A29: Different PIK3CA activation mutations can lead to distinct signaling mechanisms and EGFR inhibitor sensitivities in colorectal cancer cells

Journal Articles

Abstract B62: Multiple genomic aberrations in BCR-ABL inhibitor-resistant cells lead to sensitivity towards MEK inhibition

Marie-Claire Wagle, Matthew J. Wongchenko, Vanitha Ramakrishnan, Garret Hampton, Yibing Yan

Clin Cancer Res (2012) 18 (10_Supplement): B62.

https://doi.org/10.1158/1078-0432.MECHRES-B62

Published: 04 March 2013

View article titled, Abstract B62: Multiple genomic aberrations in BCR-ABL inhibitor-resistant cells lead to sensitivity towards MEK inhibition

Journal Articles

Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors

Yan Xin, Jessica Li, Jenny Wu, Rashell Kinard, Colin D. Weekes, Amita Patnaik, Patricia LoRusso, Rainer Brachmann, Raymond K. Tong, Yibing Yan, Ryan Watts, Shuang Bai, Priti S. Hegde

Clin Cancer Res (2012) 18 (21): 6040–6048.

https://doi.org/10.1158/1078-0432.CCR-12-1652

Published: 06 November 2012

View article titled, Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors

Includes: Supplementary data

NARROW

Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAF^V600-mutated Metastatic Melanoma

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma

Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Pathway activation signatures of breast cancer predict molecular subtype and drug sensitivity

High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing

Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068

Abstract PR6: Widespread potential for growth factor-driven resistance to anti-cancer kinase inhibitors

Abstract A29: Different PIK3CA activation mutations can lead to distinct signaling mechanisms and EGFR inhibitor sensitivities in colorectal cancer cells

Abstract B62: Multiple genomic aberrations in BCR-ABL inhibitor-resistant cells lead to sensitivity towards MEK inhibition

Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid Tumors

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only